Stock remaining very strong, despite stochastics having gone negative. To illustrate how strong NBIX stock is with the stocastics trend, the stock only is re-testing it's 9dma, which is absolutely minor by correction standards --- merely a slight pause before re-tracing. I expect the stock to challenge it's yearly high very soon, and it may very coincide with Gorman's Credit Suisse presentation on Wednesday, JMHO.
Conference season in full swing and as I said before Biotech sector will be in Rally Mode into the spring of 2016 even with the FED raising interest rates in December.
Sentiment: Strong Buy
AbbVie mentioned, and a point was made concerning the belief that ---- "Elagolix will potentially have a best in class profile with competitive efficacy and less bone loss."
Despite the last 5 session price erosion, "the damage" has been minimal, especially with volume continuing to ebb. I expect a move to re-test all-time highs, as I related before, JMHO. I thought it might occur Wednesday. Maybe, the brokerage analysts wanted to give their brokers time to get their customers in the stock before putting out their BUY CALL and raising their NBIX target price.
Do not despair the above didn't happen Wednesday. There was an excellent article, I think, put out by Seeking Alpha, done by Stephen Simpson, CFA, who surprise, surprise, claims to be a NBIX shareholder. He points out the many, many, many positives going on for NBIX. If you haven't read it, you may want to. It came out at the very close of trading Wednesday. Whether this proves to be the catalyst for NBIX's next move north, we shall see?
It only is a matter of time before others begin to realize where the growth is, as in new effective, meaningful drugs being brought to market. The earnings disappointment announcements, and the warnings have rattled investors and the marketplace. Granted NBIX, doesn't really have those earnings to worry about, yet. What it does have are significant, meaningful drugs very close to FDA approval. Neurocrine has $478 million in cash, way more than enough to survive the wait. And, the company can earn up to $500 million through milestone achievement payments from AbbVie on potential drugs they are partnered in. There are new drug phase trials for Tourette's, and essential tremors.
Too many positive to ignore. When others begin to process this, NBIX goes a lot higher.
I look at the trading range and volume over the past 10 trading days and it tells me NBIX want to break out and make a new 52 week high. We are very close to getting TS trial data.
Yesterday's NBIX performance was "disguised" --- as in the stock could have, should closed positive but, a significant buyer was controlling the trading on both, the bid and the asked level, and did not want to pay up for the shares, So the share trading range was very narrow, and "arranged/managed" over the last 5 hours of NBIX;s Monday trading day. I watched the trading very closely. Very good likelihood brokerages were getting their customers in, as the trading sizes that went on during that period, did not appear to be large --- just very persistent and relentless in what they were doing to keep the stock within a very narrow trading range. Do these things happen? You bet, especially in front of the brokerage analyst covering the company, coming out with a BUY recommendation shortly afterwards. Let's see which is the next brokerage analyst to come forward with the positive recommendation?
Volume was very large on Sept 16th, half of that on the other 3 days, so I expect a couple of days of effort to clear the level, UNLESS some important, and noteworthy, news/announcement causes a nice surge.
Surprise, surprise, NOT!!! After yesterday's disguised NBIX trading session Monday, we find out J. P. Morgan likes Neurocrine a lot, and points out it's numbers and estimates for the company are conservative.
The consensus by analysts, who are educated and paid to assess a stock's potential, is that NBIX will go to $70 in a year. In contrast, we have johnnys_meatballs , an anonymous poster on an open message board, saying the stock is going to $10. Who do you believe? Tough choice, huh?
johnny is a meatball, his short position is burning a whole in his investment portfolio.
no brag just fact
Sentiment: Strong Buy
NBIX is back where it was in July --- before Hillary, before China, before the U.S. stock market sell-off that caused investors to purge the stocks that were the leaders. Nothing has changed for Neurocrine, except they're further along with bringing effective, meaningful drugs to market. The word is spreading. Investors are looking for significant earnings plays. While Neurocrine doesn't have much in that area now, they are sitting in a sweet spot, because they are close enough to that happening, that NBIX will take on a new personality. Be prepared, because as I have insisted all along throughout, having been involved with other highly successful biotech companies who were on the verge of bringing their very first effective and meaningful drug(s) to market --- the stock will end up going a significant amount higher than anyone ever imagined it would go, JMHO having been there before.
there are analysts that have $150/share price target on GPRO. the stock is currently at $19. you really think analysts know what they are talking about?
with your logic, just look for any stock below the price target of the analyst's projection and buy. if only it were that easy. you will be slaughtered shortly.